Table 2 Summary of trials combining endocrine therapy with PI3K inhibitors in patients with metastatic hormone receptor-positive breast cancer
From: Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
Agent | ET | Setting | Trial |
|---|---|---|---|
Alpelisib | Fulvestrant | After progression on AI | SOLAR-1; NCT02437318 |
Buparlisib | Fulvestrant | After progression on AI | BELLE-2; NCT01610284 |
Buparlisib | Fulvestant | After progression on mTOR inhibitor | BELLE-3; NCT01633060 |
Pictilisib | Fulvestrant | After progression on AI | FERGI; NCT01437566 |
Pictilisib + Palbociclib | Fulvestrant | After progression on AI | PASTOR; NCT02599714 |
Gedatolisib + Palbociclib | Fulvestrant or Letrozole | 3 arms: • No prior endocrine therapy • Progression on or after 1 line of endocrine therapy, no prior CDK inhibitor therapy • Progression after 1 or 2 prior endocrine therapies, following prior CDK inhibitor therapy | NCT02684032 |